- Home
- EFC vs RVPHW Comparison
EFC vs RVPHW Comparison
Compare EFC & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFC
- RVPHW
- Stock Information
- Founded
- EFC 2007
- RVPHW 2018
- Country
- EFC United States
- RVPHW United States
- Employees
- EFC N/A
- RVPHW 15
- Industry
- EFC Real Estate
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- EFC Finance
- RVPHW Health Care
- Exchange
- EFC Nasdaq
- RVPHW Nasdaq
- Market Cap
- EFC N/A
- RVPHW N/A
- IPO Year
- EFC 2010
- RVPHW N/A
- Fundamental
- Price
- EFC $12.19
- RVPHW $0.05
- Analyst Decision
- EFC Buy
- RVPHW
- Analyst Count
- EFC 5
- RVPHW 0
- Target Price
- EFC $14.00
- RVPHW N/A
- AVG Volume (30 Days)
- EFC 1.3M
- RVPHW 22.4K
- Earning Date
- EFC 05-06-2025
- RVPHW 03-14-2025
- Dividend Yield
- EFC 12.80%
- RVPHW N/A
- EPS Growth
- EFC 52.03
- RVPHW N/A
- EPS
- EFC 1.36
- RVPHW N/A
- Revenue
- EFC $303,226,000.00
- RVPHW N/A
- Revenue This Year
- EFC N/A
- RVPHW N/A
- Revenue Next Year
- EFC $5.73
- RVPHW N/A
- P/E Ratio
- EFC $8.99
- RVPHW N/A
- Revenue Growth
- EFC 20.43
- RVPHW N/A
- 52 Week Low
- EFC $11.10
- RVPHW $0.13
- 52 Week High
- EFC $14.40
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- EFC 43.34
- RVPHW N/A
- Support Level
- EFC $11.90
- RVPHW N/A
- Resistance Level
- EFC $12.20
- RVPHW N/A
- Average True Range (ATR)
- EFC 0.46
- RVPHW 0.00
- MACD
- EFC -0.05
- RVPHW 0.00
- Stochastic Oscillator
- EFC 48.86
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.